Patent Application
20240093152
A Sequence Listing accompanies this application and is submitted as an ASCII text file of the sequence listing named “166118_01116_ST25.txt” which is 406,692 bytes in size and was created on Nov. 12, 2021. The sequence listing is electronically submitted via EFS-Web with the application and is incorporated herein by reference in its entirety.
Cultured meat, or meat produced through cell culture and tissue engineering, offers the potential to drastically alter our world's meat production system by addressing the environmental, ethical, and health concerns associated with modern animal agriculture. The high costs of current cell culture media are prohibitive to this effort as it requires many exogenous recombinant proteins and growth factors for propagation and expansion.
Therefore, bringing down the costs of this media is a key hurdle facing cultured meat's development and reaching price parity with conventional meats. The proposed approach offers a promising option, as it completely eliminates the need for the most expensive components of cell culture media, thereby drastically lowering costs.
The present invention provides modified cells that can grow in minimal media for use in cultured meat, methods of making and uses thereof. Further, the invention provides a cultured meat product comprising in vitro grown cells in minimal media. Methods of culturing cells in minimal media to make a cultured meat product are also provided.
In one aspect, the disclosure provides a modified non-human cell ectopically expressing two or more growth factors or cytokines or receptors thereof that promote cell growth, wherein the two or more factors are selected from Table 1. In some aspects, the growth of these cells do not require exogenous supplementation with growth factors.
In another embodiment, a composition comprising the modified non-human cells described herein are provided.
In a further embodiment, a meat product comprising a population of the cells described herein is provided.
In a further aspect, a method of producing a meat product in in vitro culture is provided. The method comprises culturing a population of the modified non-human cells described herein in minimal culture medium for a sufficient time to increase the number of cells, whereby the method produces a non-human animal tissue suitable for human and/or animal consumption and wherein the minimal media does not contain exogenous growth factors.
In a further aspect, the disclosure provides a method of producing a population of modified cells for making a food product, the method comprising: (a) expressing two or more factors of Table 1 in cells; (b) culturing the cells of (a) in minimal medium for a sufficient time to promote growth of cells to a sufficient number to produce a food product; wherein the minimal media does not contain exogenous growth factors.
In another aspect, the disclosure provides a method of producing a meat product in in vitro culture, the method comprising: co-culturing a population of target cells and a feeder cell population comprising the modified non-human cells described herein in minimal culture medium for a sufficient time to increase the number of target cells, whereby the method produces a non-human animal tissue suitable for human and/or animal consumption and wherein the minimal media does not contain exogenous growth factors and wherein the target cell is not genetically modified. In another aspect, a food product comprising a population of the target cells produced by the method described herein is provided.
In a further aspect, compositions and food products comprising cells made by the methods described herein are provided.
Before the present invention is described in further detail, it is to be understood that the invention is not limited to the particular embodiments described. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. The scope of the present invention will be limited only by the claims. As used herein, the singular forms “a”, “an”, and “the” include plural embodiments unless the context clearly dictates otherwise.
It should be apparent to those skilled in the art that many additional modifications beside those already described are possible without departing from the inventive concepts. In interpreting this disclosure, all terms should be interpreted in the broadest possible manner consistent with the context. Variations of the term “comprising” should be interpreted as referring to elements, components, or steps in a non-exclusive manner, so the referenced elements, components, or steps may be combined with other elements, components, or steps that are not expressly referenced. Embodiments referenced as “comprising” certain elements are also contemplated as “consisting essentially of” and “consisting of” those elements. When two or more ranges for a particular value are recited, this disclosure contemplates all combinations of the upper and lower bounds of those ranges that are not explicitly recited. For example, recitation of a value of between 1 and 10 or between 2 and 9 also contemplates a value of between 1 and 9 or between 2 and 10.
Cultured meat (also called in vitro, cell-based, cultivated, lab grown meat) prepared using tissue and bioengineering techniques in vitro is another alternative to traditional animal agriculture. By directly growing meat (muscle and fat tissue) in vitro, energy and nutrients may be more efficiently focused on the outcome. The time frame to generate cultured meat tissues in vitro is also thought to be faster compared to traditional animal agriculture, and may only require weeks as opposed to months or years for pork and beef, for example. Moreover, tight control over cell biology during tissue cultivation, as well as the production process, allows for the fine tuning of nutritional parameters by engineering muscle or fat cells to produce vital nutrients that would otherwise not be found (or found only at low concentrations) in conventional meat. Thus, cultured meat production systems may offer healthier, more efficient, and more environmentally friendly alternatives to animal-derived meats.
The technology disclosed herein exploits genetic strategies to generate “self-sufficient” cell lines that endogenously produce all of the requisite signaling molecules for growth in low cost, chemically defined cell culture media. The “self-sufficient” cell lines described herein are genetically modified or engineered to endogenously produce required molecules for growth in minimal tissue culture media. Specifically, ectopic expression of growth factors (e.g., fibroblast growth factor (FGF), transforming growth factor (TGFb), neuregulin (NRG), Insulin-like growth factor (IGF), etc.), growth factor receptors (FGF receptors, TGF receptors, NRG receptors, IGF receptors, etc.) and/or signaling/nutrient transport proteins (e.g., insulin, albumin, transferrin, etc.) ameliorate the need for the exogenous inclusion of these proteins in cell culture media. As growth factors and signaling proteins contribute over 95% of the cost of standard cell culture media, this invention could drastically lower the cost of production of cultured meats producing products that could compete pricewise with animal agriculture.
In the instant disclosure, stem cell lines from food-relevant tissues (e.g., muscle, fat, liver, connective tissue) of relevant animal species (e.g., bovine, porcine, piscine, galline) are engineered (modified) to express the aforementioned genes (and potentially others) constitutively or under controllable promoter systems allowing the necessary protein growth and propagation factors to be endogenously expressed by the cell. This allows for minimal media to be used for tissue culture, preferably wherein the minimal media does not comprise exogenous growth factors. Options for genetic engineering include insertion of cassettes, i.e., polynucleotide encoding the signaling/growth molecules (e.g. through CRISPR/Cas9, transposon-mediated, or recombinase-mediated genetic insertion), or by genetic activation of the native genes in cells.
Endogenous growth factors and signaling molecules have been produced in CHO cells and 3T3 fibroblasts to abrogate the need for these components in cell culture media (Pak et al. “Super-CHO-A cell line capable of autocrine growth under fully defined protein-free conditions”. Cytotechnology 1996 January; 22(1-3):139-46, DOI: 10.1007/BF00353933; Z Pietrzkowski, Z. et al. “Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors”. Cell Growth Differ. 1992 April; 3(4):199-205. PMID 1325181; U.S. Pat. No. 6,797,515B2, each of which are incorporated herein by reference). Specifically, these cells were engineered to express insulin or IGF, IGFR, and transferrin. While this has been demonstrated for these proteins and in CHO and 3T3 cells for pharmaceutical applications, the use in food production is novel.
In one aspect of the current disclosure, modified non-human cells ectopically expressing two or more growth factors or cytokines or receptors thereof that promote cell growth are provided. In some embodiments, the two or more factors are selected from the factors listed in Table 1.
As used herein, “factors” refer to the growth factors, cytokines, or other proteins used to generate self-sufficient cells. As used herein, “self-sufficient” refers to cells that require minimal exogenous supplementation with growth factor, or more preferably, no exogenous supplementation with growth factors. In some embodiments, factors refers to the proteins listed in Table 1. In certain contexts, factors refer to the nucleotide sequence encoding the proteins listed in Table 1.
As used herein, “ectopic” expression is refers to expression of mRNA or proteins under the control of a non-native heterologous promoter and/or enhancer. The term “ectopic” further encompasses exogenous polynucleotides that are introduced into the cell and capable of expressing the factors described herein. Thus, in some embodiments, ectopic expression is achieved through exogenous polynucleotide sequences integrated into the genome of the cells of the instant disclosure, e.g., through transposons, viral transduction, or recombination. In some embodiments, exogenous expression is achieved through polynucleotide sequences that are not integrated into the genome of the cells of the instant disclosure, but are expressed episomally. Episomes, in eukaryotes, are extrachromosomal, closed circular DNA molecules of a plasmid or a viral genome origin, that are replicated autonomously in the host cell and therefore, they bear significant vector potential for the transfer of nucleic acids into cells. Such is the case of the Replicating Episomal Vectors, that have been engineered and used for the study of gene expression and in gene therapy applications. In some embodiments, ectopic expression is achieved through activating the expression of the endogenously encoded proteins by activation through exogenously introduced elements, e.g., Tal effector-like nucleases (TALENS), zing finger nucleases (ZFN), Cas9 molecules, etc. In some embodiments, the transposons are, for example, Piggy bac or Sleeping Beauty transposons. In further embodiments, in vitro transcribed (IVT) mRNA encoding the factors is delivered to the cells.
In some embodiments, factors that are receptor ligands, e.g., growth factors, cytokines, etc. are expressed by the cells of the instant disclosure. In such embodiments, the receptor ligands may signal in an autocrine, or paracrine manner in vitro. However, in some embodiments, cytokine or growth factor receptors are also exogenously expressed in the cell. In such embodiments, the receptors may be wild type, that is, not comprising any mutations that alter their function as compared to the standard receptor known in the art. In other embodiments, receptors comprise mutations that alter their function are contemplated. In one such example, mutations may render the receptors as “constitutively active”, meaning that the receptors signal in the absence of their ligand. Several such constitutively active receptors are known in the art, for example, mutant FGF receptor. See, for example, Brewer et al. “Genetic insights into the mechanisms of Fgf signaling”, Genes Dev. 2016 Apr. 1; 30(7): 751-771, which is incorporated by reference herein. Furthermore, Overexpression or mutation of Epidermal growth factor receptor (EGFR) can also lead to constitutive expression. See, for example, Chakraborty et al. “Constitutive and ligand-induced EGFR signaling triggers distinct and mutually exclusive downstream signalling networks”, Nature Communications volume 5, Article number: 5811 (2014); and Holland et al. “A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice”, Genes & Dev. 1998. 12: 3675-3685, which are incorporated by reference herein in their entireties including, but not limited to the sequences and mutations necessary for constitutive activation. In some embodiments, EGFR mutations involve deletion of most of the extracytoplasmic domain of the receptor, resulting in a hybrid mRNA between new sequences and the truncated EGFR sequence. See, for example, Wong A. J. et al. “Structural alterations of the epidermal growth factor receptor gene in human gliomas”, PNAS Apr. 1, 1992 89 (7) 2965-2969, which is incorporated by reference herein in its entirety. In some embodiments, constitutively active PDGF is contemplated. Various mutations in PDGF result in constitutively active signaling, e.g., mutations that effect two regions within the receptor, the autoinhibitory juxtamembrane region (exon 12 mutations) and the kinase domain itself (exon 14 and exon 18 mutations). Whereas exon 14 mutations affect the upper lobe of the kinase domain, exon 18 mutations are located within the activation loop. See, for example, Bahlawane et al. “Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics”, Cell Commun Signal. 2015; 13: 21; and Heinrich, M. C. et al. “PDGFRA activating mutations in gastrointestinal stromal tumors”, Science. 2003 Jan. 31; 299(5607):708-10, which are incorporated by reference herein regarding the constitutive activation and sequences required for such activation. In some embodiments, constitutive insulin receptor is contemplated for use as a factor. See, for example, Yamada et al. “Substitution of the insulin receptor transmembrane domain with the c-neu/erbB2 transmembrane domain constitutively activates the insulin receptor kinase in vitro”, Journal Biol Chem, Volume 267, Issue 18, 25 Jun. 1992, Pages 12452-12461. In some embodiments, constitutively active FGFR as a factor is contemplated. See, for example, Rutland P et al. “Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes”, Nature Genetics volume 9, pages 173-176 (1995), which is incorporated by reference herein. Transition of T to C at nucleotide 1036 has been reported in human subjects. The resulting Cys342Arg mutation has previously been observed in a single case of Crouzon syndrome. Other mutation are a G to A transition at nucleotide 1037-Tyr for Cys, which has previously been reported in three cases of Crouzon syndrome. Other suitable mutations of FGFR2 are an A to C transversion at nucleotide 1033, changing Thr to Pro at position 341, adjacent to the Cys 342 residue. Furthermore, a mutation that replaces the cysteine at position 342 with tyrosine, thus disrupting the formation of the third immunoglobulin (Ig)-like loop in the extracellular portion of the receptor and results in constitutive activation is contemplated as a factor for use in the methods of the current disclosure. See, for example, Mangasarian et al. “Mutation associated with Crouzon syndrome causes ligand-independent dimerization and activation of FGF receptor-2”, Journal of Cell. Phys. Vol. 172, Issue 1, July 1997, pp. 117-125, which is incorporated by reference herein.
In some embodiments of the current disclosure, the population of cells is grown for the purpose of producing comestible or edible products, i.e., lab-grown meat. Therefore, the culture conditions for producing such products must be carefully controlled to ensure the safety and wholesomeness of the resulting product. Further, the culture conditions may be amenable to industrial size production and GMP. For example, all culture materials, vessels, growth factors, media, etc. must be carefully selected and controlled to prevent the growth of pathogenic organisms or introduce toxins or pollutants into the product.
In some embodiments, the cells are propagated from primary cells. The term “primary cells” refers to cells taken directly from living tissue (e.g. muscle or fat tissue of an animal or a biopsy material) and established for growth in vitro. Primary cells are contemplated to be, without limitation, fibroblasts, adipocytes, hepatocytes, etc. Primary cells usually have undergone very few population doublings in culture and are therefore more representative of the main functional component of the tissue from which they are derived in comparison to continuous (tumor or artificially immortalized) cell lines. In some embodiments, the cells are immortalized precursor cells, which are immortalized through various methods, e.g., TERT or CDK4 expression. The primary cells may be derived from an animal source described herein. The cells may be from animal source including, without limitation, from bovine, avian (e.g., chicken, quail), porcine, seafood, or murine sources. The cells may also be derived from seafood such as fish (e.g., salmon, tuna, tilapia, perch, mackerel, cod, sardine, trout, etc.), shellfish (e.g., clams, mussels, and oysters); crustaceans (e.g., lobsters, shrimp, prawns, and crayfish), echinoderms (e.g., sea urchins and sea cucumbers), and insects. In another embodiment, the cells are propagated from stem cells. In some embodiments, the stem cells are derived from an animal. In some embodiments, the stem cells are induced pluripotent stem cells that are derived from animal cells (e.g., muscle cells, fat cells, connective tissue). Methods of producing induced pluripotent stem cells are known in the art.
In other embodiments, the methods comprise using a mixture of cells, e.g., “feeder cells” and target cells in culture. As used herein, “feeder cells” are modified cells that produce factors that aid in, for example, the culturing, differentiation or overall production of “target cells”. In some embodiments, the feeder cells produce the factors in a culture system such that the target cells are not genetically modified but benefit from the factors secreted by the feeder cells which are genetically modified. In some embodiments, the feeder cells and the target cells are separated by a permeable or semi-permeable membrane. In some embodiments, the factors secreted by the feeder cells are able to cross the permeable or semi-permeable membrane and induce signaling on the target cells without contamination of the target cells with the feeder cells in the final product of the method.
The use of serum as a source of growth factors and other vital proteins is a major cost in the generation of cultured meat. Further, given that serum is derived from bovine and other animal sources and cannot be fully characterized, it provides obstacles for standardization and GMP protocol development. Therefore, methods and compositions to reduce or eliminate the costs associated with using animal serum to culture cells for comestible meat products would greatly increase the production appeal and market appeal of such products. In the instant disclosure, cells and methods to generate “self-sufficient” modified cells are provided. In some embodiments, self-sufficient cells exogenously express two or more factors selected from Table 1. In some embodiments, cells express three or more factors from Table 1. In some embodiments, cells express four or more factors from Table 1.
In order to exogenously express factors, the disclosed methods require delivering or expressing factors to enable cells to become self-sufficient. As used herein, delivering or grammatical variations thereof refer to the process of contacting the cultured cells with the delivered agent such that the agent has the intended effect on the target cell. The term expressing as used herein refers to the cells ability to produce the intended factor (e.g., protein) in the cells such that the cell is self-sufficient and does not require endogenous factors (e.g., proteins) for tissue culture growth in vitro.
In some embodiments, expression of the two or more factors is achieved by genetically modifying the cell to contain a polynucleotide(s) that encode and are capable of expressing the two or more factors. As used herein, genetic modification refers to changes in the nucleotide sequence of the genome of a cell or organism, either in a coding, i.e., a region which is transcribed into mRNA, or a non-coding region of the genome that results in a non-naturally occurring cells that is capable of expression of the factors described herein.
In some embodiments, the polynucleotides of the present disclosure may be introduced into the host cells using any of a variety of techniques, including transformation, transfection, transduction, viral infection, gene guns, or Ti-mediated gene transfer. Particular methods include calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection, or electroporation (Davis, L., Dibner, M., Battey, I., 1986 “Basic Methods in Molecular Biology”). Other methods of transformation include for example, lithium acetate transformation and electroporation (see, e.g., Gietz et al., Nucleic Acids Res. 27:69-74 (1992); Ito et al., J. Bacterol. 153:163-168 (1983); and Becker and Guarente, Methods in Enzymology 194:182-187 (1991)).
In some embodiments, the present disclosure teaches methods for introducing exogenous protein, RNA, and DNA into a cell. Various methods for achieving this have been described previously including direct transfection of protein/RNA/DNA or DNA transformation followed by intracellular expression of RNA and protein (Dicarlo, J. E. et al. “Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems.” Nucleic Acids Res (2013). doi:10.1093/nar/gkt135; Ren, Z. J., Baumann, R. G. & Black, L. W. “Cloning of linear DNAs in vivo by overexpressed T4 DNA ligase: construction of a T4 phage hoc gene display vector.” Gene 195, 303-311 (1997); Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. “Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery.” Elife 3, e04766 (2014)).
In some embodiments, the polynucleotide is a nucleic acid construct comprising a endogenous promoter linked to the polynucleotide sequence encoding the factor(s). In some embodiments, the construct is a vector. As used herein, the term “vector” refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors” (or simply, “vectors”). The term vector encompasses “plasmids”, the most commonly used form of vector. Plasmids are circular double-stranded DNA loops into which additional DNA segments, e.g., factor, may be ligated. However, other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adena-associated viruses), may also be used with the present invention. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors may be integrated into the genome of a host cell upon introduction into the host cell, and are thereby replicated along with the host genome. In one embodiment, the vectors comprise viral vectors that use viral machinery to carry the peptide to be expressed in a host cell.
In some embodiments, the vectors of the present invention further comprise heterologous nucleic acid backbone sequence. As used herein, “heterologous nucleic acid sequence” refers to a non-human nucleic acid sequence, for example, a bacterial, viral, or other non-human nucleic acid sequence that is not naturally found in a human. Heterologous backbone sequences may be necessary for propagation of the vector and/or expression of the encoded peptide. Many commonly used expression vectors and plasmids contain non-human nucleic acid sequences, including, for example, CMV promoters.
As used herein, “promoter” refers to a region of DNA where transcription of a gene is initiated. Promoter/enhancer combination (as per, for example, the Eukaryotic Promoter Data Base EPDB, through world wide web at epd.isb-sib.ch/) could also be used to drive expression. Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.
In some embodiments, muscle-cell specific promoters are used to express the factors in cultured muscle cells. See, for example, Wang et al. “Construction and analysis of compact muscle-specific promoters for AAV vectors”, Gene Therapy volume 15, pages 1489-1499 (2008); Liu et al. “Synthetic promoter for efficient and muscle-specific expression of exogenous genes”, Plasmid, Volume 106, November 2019, 102441; and Sarcar et al. “Next-generation muscle-directed gene therapy by in silico vector design”, Nature Communications volume 10, Article number: 492 (2019), which are incorporated by reference herein.
Suitable promoters for the practice of the present invention include, without limitation, constitutive, inducible, temporally regulated, developmentally regulated, chemically regulated, physically regulated (e.g., light regulated or temperature-regulated), tissue-preferred, and tissue-specific promoters. Suitable promoters include “heterologous promoters”, a term that refers to any promoter that is not naturally associated with a polynucleotide to which it is operably connected. In mammalian cells, typical promoters include, without limitation, promoters for Rous sarcoma virus (RSV), human immunodeficiency virus (HIV-1), cytomegalovirus (CMV), SV40 virus, and the like as well as the translational elongation factor EF-1α promoter or ubiquitin promoter. Those of skill in the art are familiar with a wide variety of additional promoters for use in various cell types. In some embodiments, the promoters are, without limitation, CMV, EF1a, SV40, PGK1, Ubc, Human beta actin, CAG, TRE, UAS, Ac5, and Polyhedrin promoters.
Non-limiting examples of promoters include early or late viral promoters, such as, SV40 early or late promoters, cytomegalovirus (CMV) immediate early promoters, Rous Sarcoma Virus (RSV) early promoters; eukaryotic cell promoters, such as, e.g., beta actin promoter (Ng, 1989; Quitsche et al., 1989), GADPH promoter (Alexander et al., 1988, Ercolani et al., 1988), metallothionein promoter (Karin et al., 1989; Richards et al., 1984); and concatenated response element promoters, such as cyclic AMP response element promoters (cre), serum response element promoter (sre), phorbol ester promoter (TPA) and response element promoters (tre) near a minimal TATA box. It is also possible to use human growth hormone promoter sequences (e.g., the human growth hormone minimal promoter described at Genbank, accession no. X05244, nucleotide 283-341) or a mouse mammary tumor promoter (available from the ATCC, Cat. No. ATCC 45007). A specific example could be a phosphoglycerate kinase (PGK) promoter.
“Enhancer” refers to cis-regulatory elements in the genome that cooperate with promoters to control target gene transcription. Unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes. Therefore, one of skill in the art must select appropriate promoters and, in some embodiments, enhancers to drive expression of proteins encoded on the delivered DNA molecule. See, for example, Meersseman C. et al. “Genetic variability of the activity of bidirectional promoters: a pilot study in bovine muscle”, DNA Research, Volume 24, Issue 3, June 2017, Pages 221-233, incorporated herein by reference, for potential bi-directional promoters active in bovine muscle. See, for example, Kern C. et al. “Functional annotations of three domestic animal genomes provide vital resources for comparative and agricultural research”, Nature Communications volume 12, Article number: 1821 (2021), incorporated herein by reference, for enhancers found in the muscle of chickens, pigs, and cows.
Exogenous expression molecules (polynucleotides) for use the disclosed methods may include one or more externally inducible transcriptional regulatory elements for inducible expression of the one or more transient immortalization factors. For example, polynucleotides useful in the invention may comprise an inducible promoter, such as a promoter that includes a tetracycline response element. In some aspects, the polynucleotide comprises a gene delivery system. Many gene delivery systems are known to those of ordinary skill in the art, and non-limiting examples of useful gene delivery systems include a viral gene delivery system, an episomal gene delivery system, an mRNA delivery system, or a protein delivery system. A viral gene delivery system useful in the invention may be an RNA-based or DNA-based viral vector. An episomal gene delivery system useful in the invention may be a plasmid, an Epstein-Barr virus (EBV)-based episomal vector, a yeast-based vector, a simian virus 40 (SV40)-based episomal vector, a bovine papilloma virus (BPV)-based vector, or the like.
Thus, in some embodiments, the methods of the current disclosure comprise introducing a polynucleotide to a population of cells that comprises a promoter that is inducible by addition or removal of another “induction factor” or “inducible factor”. In some embodiments, the induction factor is tetracycline or the analogue doxycycline. Other suitable induction factors are known in the art including, for example, cumate inducible, rapamycin inducible, FKCsA inducible, Abcisic acid inducible, tamoxifen inducible, blue-light inducible promoters and riboswitches.
In some embodiments, the selected factors disclosed herein are under the control of inducible promoters. In some embodiments, the inducible promoter is a tetracycline inducible promoter (TetON or TetOFF). An exemplary Tet-responsive promoter is described in WO 04/056964A2 (incorporated herein by reference). See, for example, FIG. 1 of WO 04/056964A2. In one construct, a Tet operator sequence (TetOp) is inserted into the promoter region of the vector encoding the disclosed factors. TetOp is preferably inserted upstream of the transcription initiation site, upstream or downstream from the TATA box. In some embodiments, the TetOp is immediately adjacent to the TATA box. The expression of the target protein encoding sequence is thus under the control of tetracycline (or its derivative doxycycline, or any other tetracycline analogue). Addition of tetracycline or Dox relieves repression of the promoter by a tetracycline repressor that the host cells are also engineered to express. Thus, in such embodiments, the inducible factor is tetracycline.
In the TetOFF system, a different tet transactivator protein is expressed in the tetOFF host cell. The difference is that Tet/Dox, when bind to an activator protein, is now required for transcriptional activation. Thus, such host cells expressing the activator will only activate the transcription of an shRNA encoding sequence from a TetOFF promoter at the presence of Tet or Dox.
In some embodiments, the selected factors are under the control of a cumate-inducible promoter. See U.S. patent Ser. No. 10/135,362, which is incorporated by reference herein. Thus, in such embodiments, the inducible factor is cumate, or other similar compounds. Other suitable inducible promoter systems are known in the art and can be found in, for example, Kallunki et al. Cells. 2019 August; 8(8): 796, which is incorporated by reference herein. Additional inducible promoter systems include rapamycin, abscisic acid and FK506 binding protein 12 based inducible promoter systems.
Protein and nucleic acid sequence identities are evaluated using the Basic Local Alignment Search Tool (“BLAST”) which is well known in the art (Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87: 2267-2268; Altschul et al., 1997, Nucl. Acids Res. 25: 3389-3402). The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as “high-scoring segment pairs,” between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula (Karlin and Altschul, 1990), the disclosure of which is incorporated by reference in its entirety. The BLAST programs can be used with the default parameters or with modified parameters provided by the user.
“Percentage of sequence identity” or “percent similarity” is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or peptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
The term “substantial identity” or “substantial similarity” of polynucleotide or peptide sequences means that a polynucleotide or peptide comprises a sequence that has at least 75% sequence identity. Alternatively, percent identity can be any integer from 75% to 100%. More preferred embodiments include at least: 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% compared to a reference sequence using the programs described herein; preferably BLAST using standard parameters, as described. These values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like.
“Substantial identity” of amino acid sequences for purposes of this invention normally means polypeptide sequence identity of at least 75%. Preferred percent identity of polypeptides can be any integer from 75% to 100%. More preferred embodiments include at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.7%, or 99%.
In some embodiments, “sleeping beauty” transposons are used to introduce polynucleotides into target cells. See, for example, Sharma et al: “Efficient Sleeping Beauty DNA Transposition From DNA Mini circles”, Molecular Therapy-Nucleic Acids, vol. 2, No. 2, Feb. 1, 2013, p. e74; Kacherovsky et al., “Combination of Sleeping Beauty transposition and chemically induced dimerization selection for robust production of engineered cells.” Nucleic Acids Research, vol. 40, No. 11, Jun. 1, 2012, pp. e85-e85; Kacherovsky et al: “Multiplexed 1-16 gene transfer to a human T-cell line by combining Sleeping Beauty transposon system with methotrexate selection”, Biotechnology and Bioengineering, vol. 112, No. 7, Jul. 23, 2015 (Jul. 23, 2015), pp. 1429-1436; Kay et al, “A robust system for production of minicircle DNA vectors”, Nature Biotechnology, vol. 28, No. 12, Nov. 21, 2010, pp. 1287-1289, incorporated by reference herein.
As the expression of multiple different factors in cells is required for the generation of the modified cells of the instant disclosure, ribosomal skipping sequences are used to generate several functional proteins from a single transcript. Suitably, polynucleotides encoding the factors comprise any ribosomal skipping sequence that is known in the art. In some embodiments, the ribosomal skipping sequences are 2A oligonucleotide sequences, e.g., T2A sequence (GSGEGRGSLLTCGDVEENPGP, SEQ ID NO: 66) or P2A sequence (GSGATNFSLLKQAGDVEENPGP, SEQ ID NO: 67) or combinations thereof. In some embodiments, the polynucleotides comprise internal ribosome entry sequences (IRES).
In some embodiments, the modified cells of the instant disclosure express two or more factors from Table 1, alternatively three or more factors selected from Table 1, alternatively 4 or more factors selected from Table 1, alternatively five or more factors selected from Table 1. The factors contemplated in Table 1 may be combined in a number of different combinations to provide modified cells that has superior growth properties under minimal defined media conditions as described herein. In some embodiment, the combination of the two or more factors of Table 1 are capable of increasing the growth of the modified cells in vitro in minimal defined media as compared to unmodified cells in the same minimal defined media.
In one example, the two or more factors expressed by the modified cells are selected from fibroblast growth factor (FGF), transforming growth factor (TGF), neuregulin (NRG), insulin, insulin-like growth factor (IGF), FGF-receptor (FGF-R), insulin, albumin, and combinations thereof. For example, in some embodiments, the modified cells can express (a) FGF-2, receptor FGFR1 or combination thereof; (b) transferrin; (c) insulin, insulin-like growth factor (IGF) or combination thereof; (d) recombinant albumin; (e) NRG, NRG receptor or combinations thereof; (f) TGF, TGF receptor or combinations thereof; (g) combinations of any of (a)-(f). For example, the modified cells may express any suitable combinations of factors from (a)-(f), such as, but not limited to, (a), (a) and (b), (a) and (c), (a) and (d), (a) an (e), (a) and (f), (b) and (c), (b) and (d), (b) and (e), (b) and (f), (c) and (d), (c) and (e), (c) and (f), (d) and (e), (d) and (f), (e) and (f), (a) and (b) and (c), (a) and (b) and (The d), etc. In one suitable embodiment, the modified non-human cell express factors FGF-2, NRG1, and TGF-beta3. In some embodiments, the cell further expresses albumin. In some further embodiments, the cell expresses transferrin.
In some embodiments, the cells of the instant disclosure are capable of growing in “minimal media”. The term minimal media is used interchangeable with the term “minimal defined media” and refers to media in which are the components are able to be identified and chemically defined and suitable does not contain any animal serum. As used herein, minimal media refers to media containing a carbon source (e.g., glucose), amino acids, salts, minerals, trace nutrients (e.g., vitamins), and optionally recombinant albumin or crude plant hydrolysates (e.g., to replace albumin if not endogenously produced). In a preferred example, the minimal media does not contain any growth factors. In another preferred example, the minimal media does not contain any recombinant exogenous proteins (e.g., media consists of carbon source (e.g., glucose), amino acids, salts, minerals, trace nutrients (e.g., vitamins)). Suitable chemically defined and minimal media are known in the art, for example, B8 medium (see, for example, Kuo et al. “Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture”, Stem Cell Report. 2020 Feb. 11; 14(2):256-270, which is incorporated by reference) Beefy-9 (see, for example, Sout A. J. et al. “Simple and effective serum-free medium for sustained expansion of bovine satellite cells for cell cultured meat”, doi.org/10.1101/2021.05.28.446057, which is incorporated by reference herein), essential 8 and other serum-free media with growth factors removed (see, for example, Das, M et al. “Developing a Novel Serum-Free Cell Culture Model of Skeletal Muscle Differentiation by Systematically Studying the Role of Different Growth Factors in Myotube Formation”, In Vitro Cell Dev Biol Anim. 2009 July-August; 45(7): 378-387, which is incorporated by reference herein).
As described herein, the modified cells and meat product described herein comprise two or more factors in Table 1. Table 1 comprises growth factors and their receptors, cytokines, and other protein factors that have been found to play a role in the ability to grow and propagate cells in in vitro culture. Some of the factors are described in more detail below and exemplary sequences of the factors for use in the present invention are provided for exemplary purposes only in Table 2, but the present invention is not limited thereto. Other suitable sequences and modifications may be readily ascertained and determined by one skilled in the art.
One suitable factor for practicing the invention is neuregulin (NRG). Neuregulin has been shown to have diverse functions in the development of the nervous system and play multiple essential roles in vertebrate embryogenesis including: cardiac development, Schwann cell and oligodendrocyte differentiation, some aspects of neuronal development, as well as the formation of neuromuscular synapses. Bovine neuregulin has the sequence SEQ ID NO: 1. Tilapia (Oreochromis niloticus) neuregulin has the sequence SEQ ID NO: 2.
Another suitable factor for practicing the invention is insulin. Insulin regulates the cellular uptake of glucose. Bovine insulin has the sequence SEQ ID NO: 3, Tilapia insulin has the sequence SEQ ID NO: 4.
Another suitable factor for practice of the invention is serotransferrin or transferrin. Serotransferrin is an iron binding transport protein which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. Bovine serotransferrin has the sequence SEQ ID NO: 5. Tilapia serotransferrin has the sequence SEQ ID NO: 6.
Another suitable factor for practice of the invention is fibroblast growth factor (FGF). FGF stimulates blood vessel growth and is an important player in wound healing. Bovine FGF1 has the sequence SEQ ID NO: 7. Tilapia FGF1 has the sequence SEQ ID NO: 8. Fibroblast growth factor receptor 2 (FGFR2) Bovine FGFR2 has the sequence SEQ ID NO: 11.
Another suitable factor for practice of the invention is transforming growth factor (TGF). One suitable TGF is TGF3beta (TGF3b) is a multifunctional protein that regulates embryogenesis and cell differentiation and is required in various processes such as secondary palate development. Bovine TGF3b has the sequence SEQ ID NO: 15. Tilapia TGF3b has the sequence SEQ ID NO: 16.
Another suitable factor for practice of the invention is the receptor for fibroblast growth factor-1, e.g. FGF receptor 1 (FGFR1). FGFR1 is membrane receptor involved in many cellular processes including proliferation and migration. Bovine FGFR1 has the sequence SEQ ID NO: 9. Tilapia FGFR hast the sequence SEQ ID NO: 10. In some embodiments, the modified cell of the present disclosure can express FGF-1, FGFR1, or both FGF1 and FGFR1 in the modified cell. In some embodiments, the modified cell can express a constitutively active FGFR1 receptor which is actively on even without binding of FGF, and therefore removed the need for modifying the cell to express FGF-1. See, for example, Rutland et al. supra, and Mangasarian et al., supra.
Another suitable factor for practice of the invention is insulin-like growth factor 1 (IGF-1). IGF-1 is a hormone that helps promote bone and tissue growth. Bovine IGF-1 has the sequence SEQ ID NO: 18. Tilapia IGF-1 has the sequence SEQ ID NO: 19. Insulin can also be a factor expreseed by the modified cells of the present invention. In some embodiments, the cell may express both IGF-1 and insulin. In some aspects, for example, delivery of different combinations of factors are disclosed herein. In one embodiment, mRNA is delivered to the population of cells. In another embodiment, nucleic acid sequences (e.g., DNA) encoding the factors described herein are used.
The invention of the current disclosure provides, in some embodiments, methods of generating self-sufficient modified cells. Thus, in some embodiments, factors capable of CRISPR interference (CRISPRi) and/or CRISPR activation (CRISPRa) are used in the methods and compositions of the current disclosure to allow expression of the two or more factors. In some embodiments, the present disclosure teaches methods of modulating the expression of host cell genes via CRISPRi (CRISPR interference) and CRISPRa (CRISPR activation) technologies. In some embodiments, the presently disclosed technologies utilize catalytically inactivated (i.e., nuclease-deactivated) CRISPR endonucleases that have been mutated to no longer generate double DNA stranded breaks, but which are still able to bind to DNA target sites through their corresponding guide RNAs. In some embodiments, the present disclosure refers to these catalytically inactivated CRISPR enzymes as “dead CRISPR”, or “dCRISPR” enzymes. The “dead” modifier may also be used in reference to specific CRISPR enzymes, such as dead Cas9 (dCas9), or dead Cpf1 (dCpf1).
In some embodiments, CRISPR or other suitable genome editing methods are used to modify the FGFR such that cysteine at position 342 is replaced with tyrosine, thus disrupting the formation of the third immunoglobulin (Ig)-like loop in the extracellular portion of the receptor and conferring constative activity to the receptor. This constitutive FGFR can be expressed in the cells described herein.
dCRISPR enzymes function by recruiting the catalytically inactivated dCRISPR enzyme to a target DNA sequence via a guide RNA, thereby permitting the dCRISPR enzyme to interact with the host cell's transcriptional machinery for a particular gene.
In some embodiments, The CRISPRi methods of the present disclosure utilize dCRISPR enzymes to occupy target DNA sequences necessary for transcription, thus blocking the transcription of the targeted gene (L. S. Qi et al., “Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression.” Cell. 152, 1173-1183 (2013); see also L. A. Gilbert et al., “CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes.” Cell. 154, 442-451 (2013)). In other embodiments, the CRISPRi methods of the present disclosure utilize dCRISPR enzymes translationally fused, or otherwise tethered to one or more transcriptional repression domains, or alternatively utilize modified guide RNAs capable of recruiting transcriptional repression domains to the target site (e.g., tethered via aptamers, as discussed below).
In some embodiments, the CRISPRa methods of the present disclosure employ dCRISPR enzymes translationally fused or otherwise tethered to different transcriptional activation domains, which can be directed to promoter regions by guide RNAs. (See A. W. Cheng et al., “Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.” Cell Res. 23, 1163-1171 (2013); see also L. A. Gilbert et al., “Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation.” Cell. 159, 647-661 (2014)). In other embodiments, the CRISPRa methods of the present disclosure utilize modified guide RNAs that recruit additional transcriptional activation domains to upregulate expression of the target gene (e.g., tethered via aptamers, as discussed below). In some embodiments, CRISPRa is used to activate expression of endogenous factors, for example, those listed in Table 1.
In yet other embodiments, the presently disclosed invention also envisions exploiting dCRISPR enzymes and guide RNAs to recruit other regulatory factors to target DNA sites. In addition to recruiting transcriptional repressor or activation domains, as discussed above, the dCRISPR enzymes and guide RNAs of the present disclosure can be modified so as to recruit proteins with activities ranging from DNA methylation, chromatin remodelers, ubiquitination, sumoylation. Thus, in some embodiments, the dCRISPR enzymes and guide RNAs of the present disclosure can be modified to recruit factors with methyltransferase activity, demethylase activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity, glycosylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, sumoylating activity, desumoylating activity, ribosylation activity, deribosylation activity, myristoylation activity, remodelling activity, protease activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, synthase activity, synthetase activity, demyristoylation activity, cytidine deaminase activity and any combinations thereof
In other embodiments, the dCRISPR enzymes and guide RNAs of the present disclosure can be modified to recruit one or more marker genes/composition, such as fluorescent proteins, gold particles, radioactive isotopes, GUS enzymes, or other known biological or synthetic compositions capable of being detected. This last embodiment would permit researchers to tag and track regions of a host cell's genome. As used herein, the term “cis regulatory factors” refers to any of the biological or synthetic compositions that can be recruited by the dCRISPR or guide RNAs of the present disclosure.
In some embodiments, the dCRISPR enzyme and the transcriptional modulator domain are linked via a peptide linker. A peptide linker sequence may be employed to separate the first and the second peptide components by a distance sufficient to ensure that each peptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional regions on the first and second peptides; and (3) the lack of hydrophobic or charged residues that might react with the peptide functional regions. In certain embodiments, the peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence.
In some embodiments, the present disclosure teaches the use of protein-protein interaction domains to tether the transcriptional modulator domains to the dCRISPR. Thus in some embodiments, the sequence of the dCRISPR enzyme is translationally fused to a first protein-protein interaction domain (PP1) capable of dimerizing with a second protein-protein interaction domain (PP2) that is translationally fused to the transcriptional modulator (or other cis regulatory factor). When expressed, each of the dCRISPR-PP1 and the PP2-Transcriptional Modulator will dimerize, thus recruiting the transcriptional modulator to the DNA target site. Persons having skill in the art will be aware of methods of using naturally occurring, or synthetic protein-protein interaction domains to create in-vivo dimers. (See Giescke et al., 2006 “Synthetic protein-protein interaction domains created by shuffling Cys2His2 zinc-fingers.” Mol Syst Biol 2: 2006.0011).
In other embodiments, the present disclosure also teaches modified guide RNAs with RNA aptamers capable of recruiting one or more cis regulatory factors. The RNA aptamers of the present disclosure may be operably linked to the 5′ or 3′ end of a guide RNA, and are designed so as to not affect dCRISPR binding to a DNA target site. Instead, the RNA aptamers provide an additional tether from which to recruit one or more cis regulatory factors, such as transcriptional modulators.
In some embodiments, the present disclosure teaches customized RNA aptamers designed to directly interact with one or more cis regulatory factors. In other embodiments, the present disclosure teaches use of known aptamers targeting specific sequences. Thus, in some embodiments, the present disclosure envisions guide RNAs with validated RNA aptamers, which then bind to their natural targets, which are in turn translationally fused to one or more cis regulatory factor (i.e., guide_RNA-Aptamer-Aptamer_Target-Cis_Regulatory_Factor). In some embodiments, guide RNAs that incorporate RNA aptamers to tether cis regulatory factors are referred to as scaffold RNAs (scRNAs). (Zalatan J G, et al. “Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds.” Cell. 2015; 160:339-350). The scRNAs are designed by extending the guide RNA sequence with orthogonally acting protein-binding RNA aptamers. Each scRNA can encode information both for DNA target recognition and for recruiting a specific repressor or activator protein. By changing the DNA targeting sequence or the RNA aptamers in a modular fashion, multiple dCas9-scRNAs can simultaneously activate or repress multiple genes in the same cell
For example, an improvement, termed the synergistic activation mediator (SAM) system, was achieved by adding MS2 aptamers to a guide RNA. The MS2 aptamers were designed to recruit cognate MS2 coat protein (MCP), which were fused to p65AD and heat shock factor 1 (HSF1) (Dominguez et al., 2016 “Beyond editing; repurposing CRISPR-Cas9 for precision genome regulation and interrogation” Nat Rev Mol Cel Biol January 17(1) 5-15). The SAM technology, together with dCas9-VP64, further increased endogenous gene activation compared with dCas9-VP64 alone and was shown to activate 10 genes simultaneously. (Konermann S, et al. “Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.” Nature. 2014; 517:583-588). Similar results may be achieved through the use of other validated aptamer-scaffold protein combinations, such as PP7 or com. (Zalatan J G, et al. “Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds.” Cell. 2015; 160:339-350).
In some embodiments, the present disclosure also envisions the use of double-sided aptamers capable of tethering a dCRISPR enzyme to one or more cis regulatory factors. The double-sided aptamers of the present disclosure function similarly to the aptamers discussed above, but are capable of binding both the dCRISPR protein, and the cis regulatory factor. In one illustrative example, the dCRISPR enzyme would be translationally fused to an MS2 coat protein domain, and the cis regulatory element (a VP16 domain) would be translationally fused to a PP7 domain. The double-sided RNA aptamer would comprise an MS2 binding domain on one end, and a PP7 binding domain on another end. Thus, in some embodiments, the double-sided aptamers of the present disclosure can would be expected to form the following generic structure: dCRISPR-Aptamer_Target-Aptamer_Side1-Aptamer_Side2-Aptamer_Target-Cis_Regulatory_Factor.
A non-limiting list of the transcriptional activation domains compatible with the presently disclosed invention include: fragments of transcription regulatory domains and fragments of domains having transcription regulation function of VP16, VP64, VP160, EBNA2, E1A, Ga14, Oaf1, Leu3, Rtg3, Pho4, Gln3, Gcn4, Gli3, Pip2, Pdr1, Pdr3, Lac9, Teal, p53, NFAT, Sp1 (e.g., Sp1a), AP-2 (e.g., Ap-2a), Sox2, MLL/ALL, E2A, CREB, ATF, FOS/JUN, HSF1, KLF2, NF-1L6, ESX, Oct1, Oct2, SMAD, CTF, HOX, Sox2, Sox4, VPR, RpoZ, or Nanog. In some embodiments the transcriptional activator is VPR (see Kiani S. et al., “Cas9 gRNA engineering for genome editing, activation and repression” Nature Methods 12, 1051-1054 (2015)).
In some embodiments, the nucleic acids encoding for the dCRISPR enzyme and/or the guide RNA are contained in one or more insert parts of a modular CRISPR construct of the present disclosure. Thus, in some embodiments, the modular CRISPR constructs of the present disclosure permit users to quickly and efficiently modify the construct to add or subtract insert parts encoding for different guide RNAs (e.g., guide RNAs targeting different genes, or encoding aptamers capable of recruiting different cis regulatory factors, as discussed above), or encoding different dCRISPR enzymes (e.g., dCas9, or dCpf1, or dCRISPR protein fusions with various cis regulatory factors, as discussed above).
The terms “protein,” “peptide,” and “polypeptide” are used interchangeably herein and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long. A protein, peptide, or polypeptide may refer to an individual protein or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. A protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex. A protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination thereof. A protein may comprise different domains, for example, a nucleic acid binding domain and a nucleic acid cleavage domain. In some embodiments, a protein comprises a proteinaceous part, e.g., an amino acid sequence constituting a nucleic acid binding domain.
Nucleic acids, proteins, and/or other compositions described herein may be purified. As used herein, “purified” means separate from the majority of other compounds or entities, and encompasses partially purified or substantially purified. Purity may be denoted by a weight by weight measure and may be determined using a variety of analytical techniques such as but not limited to mass spectrometry, HPLC, etc.
Polypeptide sequence identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
The terms “nucleic acid” and “nucleic acid molecule,” as used herein, refer to a compound comprising a nucleobase and an acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides. Nucleic acids generally refer to polymers comprising nucleotides or nucleotide analogs joined together through backbone linkages such as but not limited to phosphodiester bonds. Nucleic acids include deoxyribonucleic acids (DNA) and ribonucleic acids (RNA) such as messenger RNA (mRNA), transfer RNA (tRNA), etc. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage. In some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g. nucleotides and/or nucleosides). In some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms “oligonucleotide” and “polynucleotide” can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides). In some embodiments, “nucleic acid” encompasses RNA as well as single and/or double-stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule may be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA/RNA hybrid, or include non-naturally occurring nucleotides or nucleosides. Furthermore, the terms “nucleic acid,” “DNA,” “RNA,” and/or similar terms include nucleic acid analogs, i.e. analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications. A nucleic acid sequence is presented in the to 3′ direction unless otherwise indicated. In some embodiments, a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadeno sine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose); and/or modified phosphate groups (e.g., phosphorothioates and 5′-N-phosphoramidite linkages).
The term “hybridization,” as used herein, refers to the formation of a duplex structure by two single-stranded nucleic acids due to complementary base pairing. Hybridization can occur between fully complementary nucleic acid strands or between “substantially complementary” nucleic acid strands that contain minor regions of mismatch. Conditions under which hybridization of fully complementary nucleic acid strands is strongly preferred are referred to as “stringent hybridization conditions” or “sequence-specific hybridization conditions”. Stable duplexes of substantially complementary sequences can be achieved under less stringent hybridization conditions; the degree of mismatch tolerated can be controlled by suitable adjustment of the hybridization conditions. Those skilled in the art of nucleic acid technology can determine duplex stability empirically considering a number of variables including, for example, the length and base pair composition of the oligonucleotides, ionic strength, and incidence of mismatched base pairs, following the guidance provided by the art (see, e.g., Sambrook et al., 1989, Molecular Cloning—A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Wetmur, 1991, Critical Review in Biochem. and Mol. Biol. 26(3/4):227-259; and Owczarzy et al., 2008, Biochemistry, 47: 5336-5353, which are incorporated herein by reference).
In some embodiments, the present disclosure teaches the use of origins of replication to maintain (i.e., continue to replicate) a plasmid in one or more species. Persons having skill in the art will be familiar with various available origin of replication sequences. Common features of origins of replications for bacterial, archael, eukaryotic, and multicellular organisms is discussed in Leonard and Mechali, “DNA replication Origins” Cold Spring Harb Perspect Biol 2013 October; 5(10).
In some embodiments, the polynucleotides of the current disclosure comprise “selection markers”. Selection markers are factors encoded by the polynucleotide that allow selection of a cell harboring the polynucleotide. In some embodiments, selection markers are, for example, fluorescent proteins or luminescent proteins. In some embodiments, selection markers are polynucleotide sequences that encode proteins that confer resistance to antibiotics. In some embodiments, polynucleotides comprise multiple selection markers. Exemplary selection markers include puromycin, blasticidin, zeocin, G418, or hygromycin resistance. Puromycin resistance is conferred by expression of the protein with SEQ ID NO: 64. Green fluorescent protein (GFP) has the sequence SEQ ID NO: 65.
In some embodiments, the current disclosure provides a meat product comprising the modified non-human cells of the current disclosure.
In another aspect of the current disclosure, methods of producing a meat product in in vitro culture are provided. In some embodiments, the methods comprise: culturing a population of the modified non-human cells, wherein the cells are ectopically expressing two or more growth factors or cytokines or receptors thereof that promote cell growth, wherein the two or more factors are selected from the factors listed in Table 1, in minimal culture medium for a sufficient time to increase the number of cells, whereby the method produces a non-human animal tissue suitable for human and/or animal consumption and wherein the minimal media does not contain exogenous growth factors. In some embodiments, the minimal culture medium consists a combination of one or more of a carbon source, amino acids, salts, minerals, trace nutrients, and optionally crude plant hydrolysates or recombinant albumin. In some embodiments, the minimal culture medium consists a combination of one or more of a carbon source, amino acids, salts, minerals, trace nutrients, and optionally crude plant hydrolysates. In some embodiments, the minimal media contains no exogenous recombinant protein components. In some embodiments the method comprises: culturing a combination of two or more modified cells selected from muscle cell, stem cells, fat cell, and connective tissue cell in a culture to produce a three dimensional meat product suitable for human or animal consumption.
In another aspect of the current disclosure, methods of producing a population of modified cells for making a food product are provided. In some embodiments, the method comprises: (a) expressing two or more factors of Table 1 in cells; (b) culturing the cells of (a) in minimal medium for a sufficient time to promote growth of cells to a sufficient number to produce a food product; wherein the minimal media does not contain exogenous growth factors. In some embodiments, the number of modified cells produced in step (b) is increase at least 10% or more, 15% or more, 20% or more, 35% or more, 30% or more, 35% or more, 40% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, or 100% or more relative to culturing of non-modified non-human cells in the minimal medium. Suitable precentages and amounts inbetween these amounts are contemplate, e.g., 10%, 11%, 12%, 13%, 25%, 27%, 36%, etc.
In some embodiments, the methods of the instant disclosure comprise expressing two or more factors from Table 1, alternatively three or more factors selected from Table 1, alternatively 4 or more factors selected from Table 1, alternatively five or more factors selected from Table 1. The factors contemplated in Table 1 may be combined in a number of different combinations in the disclosed methods to provide modified cells that have superior growth properties under minimal defined media conditions as described herein. In some embodiments, the combination of the two or more factors of Table 1, when used in the disclosed methods, are capable of increasing the growth of the modified cells in vitro in minimal defined media as compared to unmodified cells in the same minimal defined media. In some embodiments, the number of modified cells produced in step (b) is increase at least 10% or more, 15% or more, 20% or more, 35% or more, 30% or more, 35% or more, 40% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, or 100% or more relative to culturing of non-modified non-human cells in the minimal medium.
In one example, the two or more factors of the disclosed methods are selected from fibroblast growth factor (FGF), transforming growth factor (TGF), neuregulin (NRG), insulin, insulin-like growth factor (IGF), FGF-receptor (FGF-R), insulin, albumin, and combinations thereof. For example, in some embodiments, the disclosed methods comprise expressing (a) FGF-2, receptor FGFR1 or combination thereof; (b) transferrin; (c) insulin, insulin-like growth factor (IGF) or combination thereof; (d) recombinant albumin; (e) NRG, NRG receptor or combinations thereof; (f) TGF, TGF receptor or combinations thereof; (g) combinations of any of (a)-(f). For example, the modified cells may express any suitable combinations of factors from (a)-(f), such as, but not limited to, (a), (a) and (b), (a) and (c), (a) and (d), (a) an (e), (a) and (f), (b) and (c), (b) and (d), (b) and (e), (b) and (f), (c) and (d), (c) and (e), (c) and (f), (d) and (e), (d) and (f), (e) and (f), (a) and (b) and (c), (a) and (b) and (The d), etc. In one suitable embodiment, the methods comprise expressing factors FGF-2, NRG1, and TGF-beta3. In some embodiments of the methods, the cell further expresses albumin. In some further embodiments, the cell expresses transferrin. In some embodiments, step (a) further comprises introducing one or more, two or more, or three or more exogenous vectors in the cell capable of expressing the two or more factors.
In some embodiments of the methods, the one or more exogenous vectors is a single vector capable of expressing the two or more factors, three or more factors, four or more factors or five or more factors. In some embodiments, the vector comprises ribosomal skipping sites to express the two or more factors. In some embodiments, the one or more vector constitutively expresses the two or more factors. In some embodiments, the one or more vector is and inducible vector; and the method further comprises contacting the cell with an inducible factor, wherein contact with the inducible factor induces expression of the one or more factors within the cell. In some embodiments, step (a) comprises engineering the cell via crispr/cas9 editing to either express an endogenous factor or increase the expression of the factor within the cell. In some embodiments, the cells is a muscle cell, a fat cell, a stem cell, or a connective tissue cell. In some embodiments, the cells is a bovine cell, a piscine cell, a porcine cell, or a galline cell. In some embodiments, the cells are a combination of two or more cells selected from muscle cell, a fat cell, a stem cell, or a connective tissue cell.
In another aspect of the current disclosure, a population of cells is provided. In some embodiments, the population of cells is made by the method comprising: culturing a population of the modified non-human cells, wherein the cells are ectopically expressing two or more growth factors or cytokines or receptors thereof that promote cell growth, wherein the two or more factors are selected from the factors listed in Table 1, in minimal culture medium for a sufficient time to increase the number of cells, whereby the method produces a non-human animal tissue suitable for human and/or animal consumption and wherein the minimal media does not contain exogenous growth factors. In some embodiments, the population of cells is made the method comprising: (a) expressing two or more factors of Table 1 in cells; (b) culturing the cells of (a) in minimal medium for a sufficient time to promote growth of cells to a sufficient number to produce a food product; wherein the minimal media does not contain exogenous growth factors. In some embodiments, the number of modified cells produced in step (b) is increase at least 10% or more, 15% or more, 20% or more, 35% or more, 30% or more, 35% or more, 40% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, or 100% or more relative to culturing of non-modified non-human cells in the minimal medium.
In another aspect of the current disclosure, food products are provided. In some embodiments, the food products comprise a population of cells made by the method comprising: culturing a population of the modified non-human cells, wherein the cells are ectopically expressing two or more growth factors or cytokines or receptors thereof that promote cell growth, wherein the two or more factors are selected from the factors listed in Table 1, in minimal culture medium for a sufficient time to increase the number of cells, whereby the method produces a non-human animal tissue suitable for human and/or animal consumption and wherein the minimal media does not contain exogenous growth factors. In some embodiments, the food product comprises a population of cells made the method comprising: (a) expressing two or more factors of Table 1 in cells; (b) culturing the cells of (a) in minimal medium for a sufficient time to promote growth of cells to a sufficient number to produce a food product; wherein the minimal media does not contain exogenous growth factors. In some embodiments, the number of modified cells produced in step (b) is increase at least 10% or more, 15% or more, 20% or more, 35% or more, 30% or more, 35% or more, 40% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, or 100% or more relative to culturing of non-modified non-human cells in the minimal medium. In some embodiments, the food product is a three dimensional tissue suitable for human or non-human animal consumption.
In another aspect of the current disclosure, consumable compositions are provided. In some embodiments, the compositions comprise a population of cells made by the methods described herein. In one embodiment, the composition comprises one or more target cell type made by the methods described herein. In another embodiment, the consumable composition comprising one or more populations of the non-human modified cells described herein. In one embodiment, the consumable composition is made by a method comprising: culturing a population of the modified non-human cells, wherein the cells are ectopically expressing two or more growth factors or cytokines or receptors thereof that promote cell growth, wherein the two or more factors are selected from the factors listed in Table 1, in minimal culture medium for a sufficient time to increase the number of cells, whereby the method produces a non-human animal tissue suitable for human and/or animal consumption and wherein the minimal media does not contain exogenous growth factors. In some embodiments, the compsition comprises a population of cells made the method comprising: (a) expressing two or more factors of Table 1 in cells; (b) culturing the cells of (a) in minimal medium for a sufficient time to promote growth of cells to a sufficient number to produce a food product; wherein the minimal media does not contain exogenous growth factors. In some embodiments, the number of modified cells produced in step (b) is increase at least 10% or more, 15% or more, 20% or more, 35% or more, 30% or more, 35% or more, 40% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, or 100% or more relative to culturing of non-modified non-human cells in the minimal medium. In some embodiments, the composition comprises a three dimensional tissue suitable for human or non-human animal consumption.
In some embodiments, the meat product or composition produced by the methods of the invention may be intended for consumption by human beings, non-human animals, or both. In some embodiments, the cultured meat products are food products for human consumption. In other embodiments, the cultured meat products are used for animal feed such as feed for livestock, feed for aquaculture, or feed for domestic pets.
In some embodiments, the method includes culturing myoblasts in vitro or ex vivo and allowing these cells to differentiate into specific types of muscle cells such as skeletal muscle cells or smooth muscle cells.
In some embodiments, the meat product comprises muscle cells including skeletal muscle cells, smooth muscle cells and satellite cells. In some embodiments, the meat product comprises fat cells (e.g., adipocytes). In some embodiments, the meat product comprises an extra cellular matrix secreted by specialized cells (e.g., fibroblasts). In some embodiments, the meat product comprises endothelial cells or capillary endothelium formed by endothelial cells, including, but not limited to aortic endothelial cells and skeletal microvascular endothelial cells. In some embodiments, the meat product further comprises an extracellular matrix. In some embodiments, the meat product further comprises adipocytes. In some embodiments, the meat product further comprises capillaries.
The cells may be edible cells including muscle cells, fat cells, and combinations thereof. The precursor cells may be muscle precursor cells or adipoctye precursor cells. Examples of suitable cell types include, but are not limited to, satellite cells, fat cells (i.e., adipocytes), fibroblasts, myoblasts, muscle cells, precursors thereof, and combinations thereof. The cells may be derived from primary cells of suitable animals, as described herein.
The cells may be from animal source including, without limitation, from bovine, avian (e.g., chicken, quail), porcine, seafood, or murine sources. The cells may also be derived from seafood such as fish (e.g., salmon, tuna, tilapia, etc.), shellfish (e.g., clams, mussels, and oysters); crustaceans (e.g., lobsters, shrimp, prawns, and crayfish), and echinoderms (e.g., sea urchins and sea cucumbers), and insects. In some embodiments, the cells may be engineered to produce vital nutrients such as proteins and essential fatty acids.
In some aspects, media formulations may include transgenic components to drive cell growth and/or differentiation. For example, tetracycline-responsive promoters inserted into transgenic cells may be activated by including tetracycline in the culture medium, resulting in forced expression of myogenic or adipogenic genes in edible cell lines (e.g., chicken fibroblasts, bovine satellite cells, etc.).
Bovine satellite cells may be cultured in growth media (e.g., DMEM with Glutamax, and 1% antiobiotic-antimycotic) and modified to express two or more factors described herein. In some embodiments, the method comprises a differentiation step and a growth step in minimal culture medium. In one embodiment, to differentiate satellite cells into mature myotubes, cells may be cultured to confluence and triggered for differentiation by a low growth factor environment. For example, the culture medium may shift from a growth factor-rich proliferation media to a growth factor-poor differentiation media.
Bovine fat cells may also be cultured in growth media (e.g., DMEM with Glutamax, 1% antibiotic-antimycotic). To differentiate adipogenic precursor cells into mature adipocytes, cells may be cultured to a desired confluence (e.g., 75%), and the media may then be supplemented with free fatty acid solution or the cells can be modified to express at least one of the adipogenic factors found in Table 3. An exemplary free fatty acid solution may be 50 millimolar (mM) free fatty acid solutions containing elaidic acid, erucic acid, myristoleic acid, oleic acid, palmitoleic acid, phytanic acid, and pristanic acid. To verify lipid accumulation, Oil Red O (ORO) may be used to stain differentiated cells.
Growth factors that can be used in the methods and compositions of the invention include but are not limited to platelet-derived growth factors (PDGF), insulin-like growth factor (IGF-1). PDGF and IGF-1 are known to stimulate mitogenic, chemotactic and proliferate (differentiate) cellular responses. The growth factor can be, but is not limited to, one or more of the following: PDGF, e.g., PDGF AA, PDGF BB; IGF, e.g., IGF-I, IGF-II; fibroblast growth factors (FGF), e.g., acidic FGF, basic FGF, β-endothelial cell growth factor, FGF 4, FGF 5, FGF 6, FGF 7, FGF 8, and FGF 9; transforming growth factors (TGF), e.g., TGF-P1, TGF β1.2, TGF-β2, TGF-β3, TGF-β5; bone morphogenic proteins (BMP), e.g., BMP 1, BMP 2, BMP 3, BMP 4; vascular endothelial growth factors (VEGF), e.g., VEGF, placenta growth factor; epidermal growth factors (EGF), e.g., EGF, amphiregulin, betacellulin, heparin binding EGF; interleukins, e.g., IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14; colony stimulating factors (CSF), e.g., G-CSF, GM-CSF, M-CSF; nerve growth factor (NGF); stem cell factor; hepatocyte growth factor, and ciliary neurotrophic factor.
Various cost-effective biopolymers or complex extracts from natural sources may be used as coating materials for the surfaces of culture vessels used to culture the modified cells or used in the methods disclosed herein. In some embodiments, extracellular matrix proteins and/or chemical/synthetic coatings may be used as coatings to improve cell attachment to the culture vessel and mimic in vivo cell behavior. Other types of coating materials may include commercially available products such as, but not limited to, fibronectin, laminin, vitronectin, collagen, cadherin, elastin, hyaluronic acid, poly-D-lysine, poly-L-lysine, poly-L-ornithine, concanavalin A, and other adhesive, non-toxic chemicals. Conconavalin A, laminin, and hyaluronic acid may be obtained from animal-free origins and have been shown to enhance muscle cell attachment to various biomaterials.
The structural hierarchy and marbling of the cultured tissue construct may be tunable by changing the ratio of muscle cell fibers and fat cell fibers. Warner-Bratzler shear force test may be used to assess the texture and tenderness of the cultured tissue product.
According to the present disclosure, cultured muscle provides versatile outputs that meet target metrics pertaining to properties such as texture, thermal response upon cooking, composition, nutrition, density, alignment, composition, and marbling. This cultured meat system is cost-efficient, scalable, and generates cultured meats that mimic whole muscle.
PCT application number US2021/071171 describes methods and systems to generate whole muscle meat in culture. Accordingly, PCT application number US2021/071171, filed Aug. 12, 2021 is incorporated herein by reference in its entirety. The methods of transiently expanding a population of cells in culture may be used in the bioreactors described in PCT application number US2021/071171. Thus, the instantly disclosed cells and methods for developing cultured cell populations without genetically modifying the cells are suitable for use in the systems and methods disclosed in PCT application number US2021/071171. Suitable, the methods and systems are suitable for large scale production of the modified cells of the instant invention.
In some embodiments, the compositions comprise a mixture of cells, e.g., “feeder cells” and target cells. As used herein, “feeder cells” are cells that produce factors that aid in, for example, the culturing, differentiation or overall production of “target cells”. The target cells are the cells used to produce a cultured meat product. In some embodiments, the feeder cells produce the factors in a culture system such that the target cells are not genetically modified but benefit from the factors secreted by the feeder cells which are genetically modified. In some embodiments, the feeder cells and the target cells are separated by a permeable or semi-permeable membrane. In some embodiments, the factors secreted by the feeder cells are able to cross the permeable or semi-permeable membrane and induce signaling on the target cells without contamination of the target cells with the feeder cells in the final product. In some embodiments, a meat product comprising the target cells is produced by the methods described herein, wherein the target cells are not modified. This method further allows the target cells and feeder cells to grow in minimal culture medium without the addition of exogenous growth factors, and the ability to produce a meat product that does not contain modified cells. In some embodiments, the meat product comprises the target cells and is substantially free of feeder cells or is free of feeder cells.
As used herein the terms “ingestible” and “edible” refer to compositions which can be safely taken into the body. These compositions include those which are absorbed, and those which are not absorbed as well as those which are digestible and non-digestible. As used herein, the term “chewable” refers to a composition which can be broken/crushed into smaller pieces by chewing prior to swallowing. One skilled in the art will appreciate that a suitable edible composition may be selected according to physical properties (e.g., Young's modulus, viscosity modulus, stiffness, etc.) to a desired use (e.g., consumption by a human adult).
While the above work focuses on proliferation medium, it is possible that this same technique could be used for differentiation alone or in addition to cell growth to made edible meat products. For instance, an inducible promoter system could be used to express muscle-differentiation growth factors and/or their receptors (e.g., EGF (SEQ ID NO:68), EGF receptor (SEQ ID NO:69) and IGF 4 (SEQ ID NO:70)) when the cells are triggered to differentiate.
While the above work focuses on bovine muscle cells, this could be applicable to other species (in some instances by using gene homologues from these species) and other cell types. For example, the methods can be used for making fat cells for food production (e.g., with relevant growth factors such as those mentioned above as well as fatty acid binding protein 4 (FABP4), bone morphogenic protein 4 (BMP4, SEQ ID NO:72(Bovine), SEQ ID NO:71), peroxisome proliferator activated receptor γ (PPARγ, SEQ ID NO:73), or CCAAT enhancer binding protein alpha (CEBPA, SEQ ID NO:74)). Other potential applications of the disclosed technology include the use of preadipocytes, dedifferentiated fat cells (DFAT cells), mesenchymal stem cells or other similar cells, e.g., adipose derived stem cells.
Table 4 provides a list of genes that can be ectopically expressed to induce adipogenesis in various adipogenic precursor cells. As such, in one embodiment, the present invention provides modified cells or methods of producing modified cells that express one or more factors found in Table 4. The modified cells can be made by a method comprising expressing one or more factors from Table 4 in adipose-derived stem cells. These adipose cells can be used in food products, including, in combination with muscle cells to produce a mixture of cells for the food product.
While the above work lists several relevant growth factors, a wide range of possible targets exist (along with their associated receptors), including: FGF (Fibroblast growth factor), TGF (transforming growth factor), IGF (insulin-like growth factor), PDGF (platelet-derived growth factor), CT1 (Cardiotropin), HGF (Hepatocyte growth factor), EGF (epidermal growth factor), PEDF (Pigment epithelium-derived factor), GH (growth hormone), IL-6 (interleukin 6), LIF (Leukemia inhibitory factor), TNFa (Tumor necrosis factor), VEGF (Vascular endothelial growth factor), additional options include the production of hormones or steroidal molecules and micro RNAs (miRNAs). In addition, other factors comprising the ectopic or expression of pro-proliferative metabolites are introduced.
In one embodiment, controlling signaling cascades without ectopic growth factor expression, for example, by using a constitutively active receptor for a growth factor. For instance, a mutation in the FGF receptor is known to lead to a “permanently on” status, which would lead to permanent signaling. This mutation is involved in Crouzon syndrome, and the associated mutation could induce FGF signal transduction in bovine muscle cells to achieve similar outcomes desired by the present invention. In one embodiment, Crispr/Cas9 can be used to provide the mutation into a muscle cell. In another embodiment, a vector comprising the mutant FGFr is introduced into the cell.
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Bos taurus
Oreochromis
niloticus
Bos taurus
Bos taurus
Oreochromis
niloticus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Bos taurus
Bos taurus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Bos taurus
Oreochromis
niloticus
Bos taurus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Bos taurus
Bos taurus
Oreochromis
niloticus
Synthetic
Bos taurus
Oreochromis
mossambicus
Bos taurus
Oreochromis
niloticus
Bos taurus
Synthetic
Bos taurus
Oreochromis
niloticus
Bos taurus
Oreochromis
niloticus
Bos taurus
Bos taurus
Bos taurus
Homo
sapiens
Bos taurus
The disclosed technology exploits genetic strategies to generate “self-sufficient” cell lines that endogenously produce all of the requisite signaling molecules for growth in low cost, chemically defined cell culture media. Specifically, ectopic expression of growth factors (e.g., fibroblast growth factor (FGF), transforming growth factor (TGF), neuregulin (NRG), Insulin-like growth factor (IGF), etc.), growth factor receptors (FGF receptors, TGF receptors, NRG receptors, IGF receptors, etc.) and signaling/nutrient transport proteins (e.g., insulin, transferrin, etc.) ameliorate the need for the exogenous inclusion of these proteins in cell culture media. As growth factors and signaling proteins contribute over 95% of the cost of standard cell culture media, this invention could drastically lower the cost of production of cultured meats.
In this work, stem cell lines from food-relevant tissues (e.g., muscle, fat, liver, connective tissue) of relevant animal species (e.g., bovine, porcine, piscine, galline) are engineered to express factors comprising the aforementioned genes, constitutively, or under controllable promoter systems. Options for genetic engineering include insertion of cassettes containing these genes, e.g., through CRISPR/Cas9, transposon-mediated, or recombinase-mediated genetic insertion, or by activating the expression of the endogenous genes in cells. In the preliminary work, transposon-mediated insertion of FGF2, TGF-beta3, and NRG1 and their corresponding receptors are demonstrated. However, more directed engineering strategies such as CRISPR/Cas9 also be utilized along with additional proteins, including insulin and transferrin. A full list of relevant potential genes is included in Table 1.
Cultured meat—or meat produced through cell culture and tissue engineering—offers the potential to drastically alter our world's meat production system by addressing the environmental, ethical, and health concerns associated with modern animal agriculture. The high costs of current cell culture media are prohibitive to this effort. Therefore, bringing down the costs of this media is a key hurdle facing cultured meat's development and reaching price parity with conventional meats. The proposed approach offers a promising option, as it completely eliminates the need for the most expensive components of cell culture media, thereby drastically lowering costs.
Endogenous growth factors and signaling molecules have been produced in CHO cells and 3T3 fibroblasts to abrogate the need for these components in cell culture media (DOI: 10.1007/BF00353933; PMID 1325181; U.S. Pat. No. 6,797,515B2). Specifically, these cells were engineered to express insulin or IGF, IGFR, and transferrin. While this has been demonstrated for these proteins and in CHO and 3T3 cells for pharmaceutical applications, the use in food production is novel. Additionally, the growth factors that are most relevant for food-relevant stem cells (e.g., FGF, TGF) are not mentioned or explored in these past examples.
Growth of engineered cells: Engineered bovine satellite cells (shown in
After the data in
FGF-2 and FGFR1 co-expression: To explore how co-expression of relevant growth factors and growth factor receptors can improve upon results in
Cells capable of growth in fully protein-free-medium: The ultimate extension of the above-described work is to generate cells which are capable of growing in medium that contains no recombinant protein components. These cells would need to ectopically express, for instance: FGF-2 with or without FGFR1; insulin or insulin-like growth factor (IGF) with or without the insulin/IGF receptor; Transferrin; Albumin (unless albumin were replaced in the media with something such as plant hydrolysates3); and potentially NRG and TGF with or without respective receptors (though it may be the case that these growth factors are less necessary to the media and so could be removed without ectopically expressing them in cells—Supplementary
The above work uses the Sleeping Beauty transposition system; however, other options include CRISPR/Cas systems, TALENS, ZFNs, viral delivery (e.g., lentivirus), other transposons (e.g., Piggy Bac), gene plasmids, or transient tools (e.g., mRNAs, siRNAs, small molecules, etc.) which are well known in the art.
This application is related to, claims priority to, and incorporates herein by reference for all purposes U.S. Provisional Patent Application 63/112,682, filed Nov. 12, 2020.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US21/72383 | 11/12/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63112682 | Nov 2020 | US |
